Literature DB >> 18162765

t(8;13)-positive bilineal lymphomas: report of 6 cases.

Francisco Vega1, L Jeffrey Medeiros, Rajayogesh Davuluri, Candy C Cromwell, Serhan Alkan, Lynne V Abruzzo.   

Abstract

The 8p11 myeloproliferative syndrome (EMS) is a rare hematologic malignancy characterized by myeloid hyperplasia, eosinophilia, and precursor lymphoblastic lymphoma, associated with balanced translocations involving chromosome 8p11, most commonly t(8;13)(p11;q12). Approximately 75% of EMS patients present with or develop precursor T-cell lymphoblastic lymphoma, and most subsequently develop acute myeloid leukemia. Here we describe the morphologic and immunophenotypic features of 6 cases of t(8;13)-positive bilineal lymphoma of mixed T-cell and myeloid lineage, 5 in lymph nodes and 1 in breast. The patients, 3 males and 3 females, ranged in age from 6 to 19 years. Histologically, each tumor was composed of 2 distinct cellular components: small to medium-sized T cells with scant cytoplasm that resembled lymphoblasts, and larger immature-appearing cells with more abundant eosinophilic cytoplasm that resembled myeloblasts, a subset of which expressed myeloid antigens. In all cases, the latter component tended to surround residual lymphoid follicles and/or blood vessels. Numerous eosinophils and prominent high endothelial venules were present in all of the lymph node specimens. Interestingly, cells of both components expressed CD3 on immunohistochemical stains. In conclusion, EMS associated with t(8;13) should be suspected in patients with a bilineal tumor that involves lymph nodes or other extramedullary sites. We believe that these bilineal neoplasms of mixed T-cell and myeloid lineages, which present as lymphoma, are analogous to bilineal leukemias. They likely arise from an early hematopoietic cell with potential to differentiate along T-cell and myeloid pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18162765     DOI: 10.1097/PAS.0b013e31814b226e

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.

Authors:  Mingqiang Ren; Haiyan Qin; Ruizhe Ren; Josephine Tidwell; John K Cowell
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 2.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

3.  Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.

Authors:  MingQiang Ren; John K Cowell
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

4.  Myeloproliferative Syndrome With Eosinophilia Associated With Translocation t(8; 13) and T-cell Lymphoblastic Lymphoma: A Case Report and Review of the Literature.

Authors:  Lizeth Yamile Urrea Pineda; Oliver Perilla; Vanessa Santiago-Pacheco; Simon Trujillo Montoya
Journal:  Cureus       Date:  2022-03-01

Review 5.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

6.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.

Authors:  J Han J M van Krieken
Journal:  J Hematop       Date:  2008-07       Impact factor: 0.196

7.  Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.

Authors:  Mingqiang Ren; Haiyan Qin; Eiko Kitamura; John K Cowell
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

8.  Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.

Authors:  M Ren; H Qin; R Ren; J K Cowell
Journal:  Leukemia       Date:  2012-07-11       Impact factor: 11.528

9.  The First Case of Non-leukemic Sarcoma Composed of Mixed-phenotype Acute Leukemia, B/myeloid, Not Otherwise Specified.

Authors:  Teruhito Takakuwa; Takahiko Nakane; Masahiko Ohsawa; Joji Nagasaki; Yasutaka Aoyama; Mistutaka Nishimoto; Yoshiki Hayashi; Yuko Kuwae; Masayuki Hino; Hirohisa Nakamae
Journal:  Intern Med       Date:  2017-12-21       Impact factor: 1.271

10.  A Rare Extramedullary and Extralymphoid Presentation of Mixed Phenotypic Blastic Hematolymphoid Neoplasm: A Study of Two Cases.

Authors:  Kiran Ghodke; Prashant Tembhare; Nikhil Patkar; P G Subramanian; Brijesh Arora; Sumeet Gujral
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Jul-Sep
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.